Zeid Kayali, MD
Internal Medicine · Colton, CANPI 1396777538
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $193,061 of the $219,776 with a category attached, or 87.8%. 30 manufacturers reported payments, led by Gilead at 31.3% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 747 payments — averaging $294.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$69K
- AbbVie$67K
- Madrigal Pharmaceuticals$50K
- Exelixis Inc.$23K
- Intercept Pharmaceuticals, Inc.$5K
- Pfizer$2K
- plus $4K from 24 others
Across 2,090 payments — averaging $6708.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$1.8M
- Boehringer Ingelheim$1.8M
- Mallinckrodt Hospital Products Inc.$1.5M
- Eli Lilly$1.3M
- Genentech, Inc.$1.1M
- X4 Pharmaceuticals, Inc.$749K
- plus $5.8M from 29 others
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$193,06188%
- Travel & lodging$9,9935%
- Food & beverage$16,5188%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 157 | $68,695 |
| AbbVie | 253 | $66,811 |
| Madrigal Pharmaceuticals | 53 | $50,109 |
| Exelixis Inc. | 22 | $23,440 |
| Intercept Pharmaceuticals, Inc. | 35 | $4,823 |
| Pfizer | 31 | $2,315 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 92 | $1,192 |
| Bristol Myers Squibb | 36 | $527 |
| Sanofi | 14 | $391 |
| Shionogi Inc | 6 | $354 |
| Ipsen Biopharmaceuticals, Inc | 2 | $228 |
| Eisai Inc. | 7 | $132 |
| Albireo Pharma, Inc. | 5 | $95 |
| Phathom Pharmaceuticals, Inc. | 2 | $63 |
| Dova Pharmaceuticals | 3 | $62 |
| Merck | 4 | $61 |
| Ardelyx, Inc. | 4 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $56 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Mirum Pharmaceuticals, Inc. | 2 | $37 |
| Capsovision, Inc. | 2 | $35 |
| Orphalan Inc | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| Dynavax Technologies Corporation | 2 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $13 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$219,776 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 114 | $404,788 |
| EpclusaSofosbuvir/Velpatasvir | 13 | $312,233 |
| VemlidyTenofovir Alafenamide | 125 | $211,751 |
| RezdiffraResmetirom | 31 | $122,243 |
| RinvoqUpadacitinib | 19 | $116,847 |
| Ursodiol | 147 | $18,751 |
| Tacrolimus | 44 | $9,270 |
| Tenofovir Disoproxil Fumarate | 22 | $9,006 |
| Mycophenolate Mofetil | 86 | $7,273 |
| EliquisApixaban | 13 | $7,144 |
| LinzessLinaclotide | 11 | $6,788 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 30 | $3,934 |
| Azathioprine | 103 | $3,301 |
| Spironolactone | 195 | $2,890 |
| Lactulose | 104 | $2,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $68,695 | $523,985138 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $1,192 | $408,722144 claims |
| AbbVieRinvoq, Linzess | $66,811 | $123,63530 claims |
| Madrigal PharmaceuticalsRezdiffra | $50,109 | $122,24331 claims |
| PfizerEliquis | $2,315 | $7,14413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Colton
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.